摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,4-dioxaspiro[4.4]non-7-ene | 6671-84-7

中文名称
——
中文别名
——
英文名称
1,4-dioxaspiro[4.4]non-7-ene
英文别名
——
1,4-dioxaspiro[4.4]non-7-ene化学式
CAS
6671-84-7
化学式
C7H10O2
mdl
——
分子量
126.155
InChiKey
ODUFFDQWSHTZQV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    183.6±40.0 °C(Predicted)
  • 密度:
    1.11±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    9
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.71
  • 拓扑面积:
    18.5
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    1,4-dioxaspiro[4.4]non-7-ene间氯过氧苯甲酸 作用下, 以 二氯甲烷 为溶剂, 生成 C5H8O2C2H2O
    参考文献:
    名称:
    Synthesis and Protein Kinase C Inhibitory Activities of Balanol Analogs with Replacement of the Perhydroazepine Moiety
    摘要:
    Balanol is a potent protein kinase C (PKC) inhibitor that is structurally composed of a benzophenone diacid, a 4-hydroxybenzamide, and a perhydroazepine ring. A number of balanol analogs in which the perhydroazepine moiety is replaced have been synthesized and their biological activities evaluated against both PKC and cAMP-dependent kinase (PKA). The results suggested that the activity and the isozyme/kinase selectivity of these compounds are largely related to the conformation about this nonaromatic structural element of the molecules.
    DOI:
    10.1021/jm960497g
  • 作为产物:
    描述:
    potassium tert-butylate 作用下, 以 乙醚乙腈 为溶剂, 反应 10.0h, 生成 1,4-dioxaspiro[4.4]non-7-ene
    参考文献:
    名称:
    Jeffery, Stephen M.; Sutherland, Alan G.; Pyke, Simon M., Journal of the Chemical Society. Perkin transactions I, 1993, # 19, p. 2317 - 2328
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Trimethysilyl triflate in organic synthesis11Part 11 of this series. Part 10: S. Murata and R. Noyori, Tetrahedron Letters 2107 (1981).
    作者:R. Noyori、S. Murata、M. Suzuki
    DOI:10.1016/s0040-4020(01)93263-6
    日期:——
    Trimethylsilyl triflate is a powerful silylating agent for organic compounds and acts as a catalyst which accelerates a variety of nucleophilic reactions in aprotic media. The reactions proceed via one-center, electrophilic coordination of the silyl group to hetero functional groups and exhibit unique selectivities.
    三氟甲磺酸三甲基甲硅烷基酯是有机化合物的强大甲硅烷基化剂,并充当催化剂,可加速非质子介质中的各种亲核反应。反应通过甲硅烷基与杂官能团的单中心亲电配位进行,并表现出独特的选择性。
  • 阿片受体激动剂及其应用
    申请人:四川海思科制药有限公司
    公开号:CN109206417B
    公开(公告)日:2023-01-03
    本申请描述了可以用作阿片受体配体的化合物及其盐,及制备方法和含有该化合物的组合物,及其可以作为μ阿片受体激动剂的用途,用于治疗μ阿片受体介导的相关疾病,如疼痛和疼痛相关的紊乱。
  • NOVEL COMPOUNDS
    申请人:Takeda Pharmaceutical Company Limited
    公开号:US20150232460A1
    公开(公告)日:2015-08-20
    The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein L, X, R a , R b , R 1 , R 2 and R 3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    本发明提供了公式(I)的化合物及其药用盐,其中L、X、Ra、Rb、R1、R2和R3如规范中定义,以及其制备方法、含有它们的药物组合物以及它们在治疗中的用途。
  • FUNCTIONALIZED LINEAR AND CYCLIC POLYOLEFINS
    申请人:CALIFORNIA INSTITUTE OF TECHNOLOGY
    公开号:US20160215089A1
    公开(公告)日:2016-07-28
    This invention relates to methods and compositions for preparing linear and cyclic polyolefins. More particularly, the invention relates to methods and compositions for preparing functionalized linear and cyclic polyolefins via olefin metathesis reactions. Polymer products produced via the olefin metathesis reactions of the invention may be utilized for a wide range of materials applications. The invention has utility in the fields of polymer and materials chemistry and manufacture.
    本发明涉及制备线性和环状聚烯烃的方法和组合物。更具体地说,本发明涉及通过烯烃交换反应制备官能化线性和环状聚烯烃的方法和组合物。通过本发明的烯烃交换反应制备的聚合物产品可以用于广泛的材料应用。本发明在聚合物和材料化学及制造领域具有实用性。
  • Cycloalkyl and heterocycloalkyl compounds as orexin receptor antagonists
    申请人:Takeda Pharmaceutical Company Limited
    公开号:US09156829B2
    公开(公告)日:2015-10-13
    The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    本发明提供了公式(I)的化合物及其药学上可接受的盐,其中L、X、Ra、Rb、R1、R2和R3如规范中所定义,以及其制备过程、含有它们的药物组合物和它们在治疗方面的用途。
查看更多